Abstract
No public abstract is available from the verified source records.
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureDaniel Oppermann Peixoto, Juciano Gasparotto, Olajide Raymond Ojo, Olayemi Philemon Aro, Umin-Awaji Sunday Godswill, Luiza Franco de Abreu, Luana Carneiro Lopes, José Claudio Fonseca Moreira, Daniel Pens Gelain
Abstract
Authors
Institutions
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Cognitive decline in Parkinson disease
10.1038/nrneurol.2017.27 · 2017
A systematic review of prevalence studies of dementia in Parkinson's disease
10.1002/mds.20527 · 2005
Increased AGE-RAGE axis stress in methamphetamine abuse and methamphetamine-induced psychosis: associations with oxidative stress and increased atherogenicity
10.1111/adb.13333 · 2023
CSF Aβ42 predicts early-onset dementia in Parkinson disease
10.1212/wnl.0000000000000425 · 2014
Functions of p38 MAP Kinases in the Central Nervous System
10.3389/fnmol.2020.570586 · 2020
The p38(MAPK)-MK2 Signaling Axis as a Critical Link Between Inflammation and Synaptic Transmission
10.3389/fcell.2021.635636 · 2021
Parkinson's disease
10.1016/s0140-6736(21)00218-x · 2021
Brain-first versus gut-first parkinson's disease: a hypothesis
2019
Development of azeliragon, an oral small molecule antagonist of the receptor for advanced glycation endproducts, for the potential slowing of loss of cognition in mild alzheimer's disease
10.14283/jpad.2018.18 · 2018
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
unpaywall
Confidence 95%
datacite
Confidence 0%
Hypertension induces brain β-amyloid accumulation, cognitive impairment, and memory deterioration through activation of receptor for advanced glycation end products in brain vasculature
10.1161/hypertensionaha.112.195511 · 2012
Aβ-AGE aggravates cognitive deficit in rats via RAGE pathway
10.1016/j.neuroscience.2013.10.056 · 2014
P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model
10.1172/jci25247 · 2005
Lewy body cortical involvement may not always predict dementia in Parkinson's disease
10.1136/jnnp.74.7.852 · 2003
Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson's disease
10.1002/mds.22594 · 2009
10.1093/brain/awr031
10.1093/brain/awr031
Oxidative stress in Alzheimer's disease hippocampus: a topographical study
10.1016/j.jns.2010.08.029 · 2010
Cerebral Hypoxia-Induced Molecular Alterations and Their Impact on the Physiology of Neurons and Dendritic Spines: A Comprehensive Review
10.1007/s10571-024-01491-4 · 2024
Systemic inflammation induces acute behavioral and cognitive changes and accelerates neurodegenerative disease
10.1016/j.biopsych.2008.07.024 · 2009
Evidence of oxidative stress in the neocortex in incidental Lewy body disease
10.1097/01.jnen.0000179050.54522.5a · 2005
RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain
10.1038/nm890 · 2003
A multimodal RAGE-specific inhibitor reduces amyloid beta-mediated brain disorder in a mouse model of Alzheimer disease
10.1172/jci58642 · 2012
LRP/amyloid β-peptide interaction mediates differential brain efflux of Aβ isoforms
10.1016/j.neuron.2004.07.017 · 2004
The endotoxin delivery protein HMGB1 mediates caspase-11-dependent lethality in sepsis
10.1016/j.immuni.2018.08.016 · 2018
The Receptor for Advanced Glycation Endproducts (RAGE) and Mediation of Inflammatory Neurodegeneration
10.4172/2161-0460.1000421 · 2018
Sex differences distinguish performance in four object recognition-based memory tasks in the Pink1-/- rat model of Parkinson's disease
10.1016/j.physbeh.2025.115034 · 2025
RAGE, LRP-1, and amyloid-beta protein in Alzheimer's disease
10.1007/s00401-006-0115-3 · 2006
Pathophysiology of RAGE in inflammatory diseases
10.3389/fimmu.2022.931473 · 2022
Circulating levels of soluble receptor for advanced glycation end products in Alzheimer disease and vascular dementia
10.1001/archneur.62.11.1734 · 2005
The use of the soluble receptor for advanced glycation-end products (sRAGE) as a potential biomarker of disease risk and adverse outcomes
10.1016/j.redox.2021.101958 · 2021
HMGB1/RAGE signaling mediates the activation of microglia and participates in depressive-like behaviors and cognitive deficits in rats after ischemia-reperfusion
10.1016/j.bbr.2025.115662 · 2025
RAGE-dependent signaling in microglia contributes to neuroinflammation, Abeta accumulation, and impaired learning/memory in a mouse model of Alzheimer's disease
10.1096/fj.09-139634 · 2010
CNS infections, sepsis and risk of Parkinson's disease
10.1093/ije/dys052 · 2012
The redox state of the alarmin HMGB1 is a pivotal factor in neuroinflammatory and microglial priming: A role for the NLRP3 inflammasome
10.1016/j.bbi.2015.10.009 · 2016
Metabolic derangements contribute to reduced sRAGE isoforms in subjects with Alzheimer's disease
10.1155/2018/2061376 · 2018
Clinical trial of an inhibitor of RAGE-Abeta interactions in Alzheimer disease
10.1212/wnl.0000000000000364 · 2014
Targeting the RAGE–RIPK1 binding site attenuates diabetes-associated cognitive deficits
10.1186/s12974-025-03489-1 · 2025
Traumatic brain injury in later life increases risk for Parkinson disease
10.1002/ana.24396 · 2015
Receptor for advanced glycation end products mediates sepsis-triggered amyloid-beta accumulation, Tau phosphorylation, and cognitive impairment
10.1074/jbc.m117.786756 · 2018
Targeted inhibition of RAGE in substantia nigra of rats blocks 6-OHDA-induced dopaminergic denervation
10.1038/s41598-017-09257-3 · 2017
RAGE Against the Glycation Machine in Synucleinopathies: Time to Explore New Questions
2023
Endothelial RAGE exacerbates acute postischaemic cardiac inflammation
10.1160/th15-11-0898 · doi-reference
Binding of RAGE and RIPK1 induces cognitive deficits in chronic hyperglycemia-derived neuroinflammation
10.1111/cns.14449 · doi-reference
Central role for PICALM in amyloid-β blood-brain barrier transcytosis and clearance
10.1038/nn.4025 · doi-reference
Inhibitor Development for α-Synuclein Fibril's Disordered Region to Alleviate Parkinson's Disease Pathology
10.1021/jacs.4c08869 · doi-reference
Ectodomain shedding of the receptor for advanced glycation end products: a novel therapeutic target for Alzheimer's disease
10.1007/s00018-009-0121-4 · doi-reference
RAGE in circulating immune cells is fundamental for hippocampal inflammation and cognitive decline in a mouse model of latent chronic inflammation
10.1016/j.bbi.2023.12.022 · doi-reference
MD-2 is required for disulfide HMGB1-dependent TLR4 signaling
10.1084/jem.20141318 · doi-reference
Targeting Inflammation Driven by HMGB1
10.3389/fimmu.2020.00484 · doi-reference
RAGE Signaling pathway in hippocampus dentate gyrus involved in GLT-1 decrease induced by chronic unpredictable stress in rats
10.1016/j.brainresbull.2020.06.020 · doi-reference
RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease
10.1038/382685a0 · doi-reference
Vascular RAGE transports oxytocin into the brain to elicit its maternal bonding behaviour in mice
10.1038/s42003-019-0325-6 · doi-reference
Septic shock is associated with receptor for advanced glycation end products ligation of LPS
10.4049/jimmunol.1002253 · doi-reference
Multimodal PET Imaging of Amyloid and Tau Pathology in Alzheimer Disease and Non-Alzheimer Disease Dementias
10.1016/j.cpet.2017.02.005 · doi-reference
Associations Between Tau, β-Amyloid, and Cognition in Parkinson Disease
10.1001/jamaneurol.2017.3713 · doi-reference
The CamPaIGN study of Parkinson's disease: 10-year outlook in an incident population-based cohort
10.1136/jnnp-2013-305277 · doi-reference
Using mice to model Alzheimer's dementia: an overview of the clinical disease and the preclinical behavioral changes in 10 mouse models
10.3389/fgene.2014.00088 · doi-reference
Synthetic Fragment of Receptor for Advanced Glycation End Products Prevents Memory Loss and Protects Brain Neurons in Olfactory Bulbectomized Mice
10.3233/jad-170483 · doi-reference
RAGE does not affect amyloid pathology in transgenic ArcAβ mice
10.1159/000261723 · doi-reference
Glycation potentiates alpha-synuclein-associated neurodegeneration in synucleinopathies
10.1093/brain/awx056 · doi-reference
Glycation in Parkinson's disease and Alzheimer's disease
10.1002/mds.26566 · doi-reference
Glycation of alpha-synuclein enhances aggregation and neuroinflammatory responses
10.1038/s41531-025-01159-w · doi-reference
The impact of neuroinflammation on neuronal integrity
10.1111/imr.13419 · doi-reference
Clearance systems in the brain-implications for Alzheimer disease
10.1038/nrneurol.2015.119 · doi-reference
Vagotomy and subsequent risk of Parkinson's disease
10.1002/ana.24448 · doi-reference
Hospital-treated infections in early- and mid-life and risk of Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis: A nationwide nested case-control study in Sweden
10.1371/journal.pmed.1004092 · doi-reference
The concerted amyloid-beta clearance of LRP1 and ABCB1/P-gp across the blood-brain barrier is linked by PICALM
10.1016/j.bbi.2018.07.017 · doi-reference
Assessing behavior and cognition in rodents, nonhuman primates, and humans: where are the limits of translation?
10.31887/dcns.2019.21.3/mrossner · doi-reference
Early-stage Parkinson's disease detection using multimodal brain-body biomarkers from fNIRS and IMU data
10.1016/j.compbiomed.2025.111096 · doi-reference
Extracellular HSP70 Activates ERK1/2, NF-kappa B and Pro-Inflammatory Gene Transcription Through Binding with RAGE in A549 Human Lung Cancer Cells
10.1159/000480213 · doi-reference
Neuroimaging and cognition in Parkinson's disease dementia
10.1111/j.1750-3639.2009.00368.x · doi-reference
Anti-RAGE antibody attenuates isoflurane-induced cognitive dysfunction in aged rats
10.1016/j.bbr.2017.01.012 · doi-reference
Translational Assays for Assessment of Cognition in Rodent Models of Alzheimer's Disease and Dementia
10.1007/s12031-016-0837-1 · doi-reference
An increased rate of longitudinal cognitive decline is observed in Parkinson's disease patients with low CSF Aβ42 and an APOE ε4 allele
10.1016/j.nbd.2019.02.023 · doi-reference
In-vivo evidence that high mobility group box 1 exerts deleterious effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model and Parkinson's disease which can be attenuated by glycyrrhizin
10.1016/j.nbd.2016.02.018 · doi-reference
Deletion of RAGE causes hyperactivity and increased sensitivity to auditory stimuli in mice
10.1371/journal.pone.0008309 · doi-reference
Classifying neurocognitive disorders: the DSM-5 approach
10.1038/nrneurol.2014.181 · doi-reference
PF-04494700, an oral inhibitor of receptor for advanced glycation end products (RAGE), in Alzheimer disease
10.1097/wad.0b013e318204b550 · doi-reference
Parkinson disease with dementia: comparing patients with and without Alzheimer pathology
10.1097/wad.0b013e31819c5ef4 · doi-reference
Enteric glia in homeostasis and disease: From fundamental biology to human pathology
10.1016/j.isci.2021.102863 · doi-reference
A review of methods used to study cognitive deficits in Parkinson's disease
10.1179/1743132812y.0000000118 · doi-reference